SLC45A2

Across TCGA pan-cancer cohorts, SLC45A2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC45A2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SLC45A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC45A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, DLBC, and LUSC are the cancer types where SLC45A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
LUSC	OS	Median	III,IV	0.176	0.575	.006	26	view →
CESC	OS	Median	II,III,IV	0.242	0.764	.016	24	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	14	view →
PAAD	DFS	Median	All	0.060	0.484	<.001	12	view →
UCEC	DFS	Median	All	0.965	0.612	.012	8	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC45A2–OV (OS)

Open the OV breakdown →